Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure-Reference-Cited by-同舟云学术

Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure

Published:2015-12-01 Issue:12 Volume:100 Page:4541-4552
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Bagger Jonatan Ising¹²,Holst Jens Juul²,Hartmann Bolette²,Andersen Birgitte³,Knop Filip Krag¹²,Vilsbøll Tina¹

Affiliation:

1. Center for Diabetes Research (J.I.B., F.K.K., T.V.), DK-2900 Hellerup, Denmark

2. Gentofte Hospital, and NNF Center for Basic Metabolic Research and Department of Biomedical Sciences (J.I.B., J.J.H., B.H., F.K.K.), Faculty of Health Sciences, University of Copenhagen, DK-2900 Hellerup, Denmark

3. Diabetes Research Unit (B.A.), Novo Nordisk A/S, DK-2760 Måløv, Denmark

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/100/12/4541/10422411/jcem4541.pdf

Reference40 articles.

1. Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man;Schjoldager;Eur J Clin Invest,1988

2. Oxyntomodulin inhibits food intake in the rat;Dakin;Endocrinology,2001

3. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial;Wynne;Diabetes,2005

4. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial;Wynne;Int J Obes,2006

5. Glucagon-like peptide-1-(7–36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line;Gros;Endocrinology,1993

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity;Diabetes, Obesity and Metabolism;2024-06-09

2. Incretin and glucagon receptor polypharmacology in chronic kidney disease;American Journal of Physiology-Endocrinology and Metabolism;2024-06-01

3. Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence;Journal of Endocrinology;2024-04-03

4. Dual glucagon‐like peptide‐1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity;Diabetes, Obesity and Metabolism;2024-04

5. Glucagon and the metabolic syndrome;Metabolic Syndrome;2024